S Claiborne Johnston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11863296/publications.pdf

Version: 2024-02-01

204 papers 34,486 citations

14653 66 h-index 181 g-index

208 all docs

208 docs citations

208 times ranked 25767 citing authors

#	Article	IF	CITATIONS
1	Aligning academic medicine within the healthcare system: the APS-SPR virtual chat series. Pediatric Research, 2023, 93, 503-510.	2.3	2
2	Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack. Annals of Neurology, 2022, 91, 380-388.	5.3	4
3	Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy. JAMA Neurology, 2022, 79, 244.	9.0	7
4	Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial. Journal of the American Heart Association, 2022, 11, e023223.	3.7	6
5	Real-time pandemic surveillance using hospital admissions and mobility data. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	31
6	Time to Retire the Concept of <i>Transient Ischemic Attack</i> . JAMA - Journal of the American Medical Association, 2022, 327, 813.	7.4	23
7	Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. Stroke and Vascular Neurology, 2022, 7, e001480.	3.3	2
8	Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology, 2022, 99, .	1.1	7
9	Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry <i>CYP2C19</i> Loss-of-Function Alleles. JAMA Neurology, 2022, 79, 739.	9.0	7
10	The Concept of Transient Ischemic Attackâ€"Reply. JAMA - Journal of the American Medical Association, 2022, 327, 2457.	7.4	1
11	Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke. JAMA Neurology, 2021, 78, 177.	9.0	17
12	F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA. Neurology, 2021, 96, e1-e9.	1.1	3
13	Newly Diagnosed Atrial Fibrillation After Transient Ischemic Attack Versus Minor Ischemic Stroke in the POINT Trial. Journal of the American Heart Association, 2021, 10, e019362.	3.7	3
14	Design of COVID-19 staged alert systems to ensure healthcare capacity with minimal closures. Nature Communications, 2021, 12, 3767.	12.8	27
15	Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial. JAMA Network Open, 2021, 4, e2112551.	5.9	7
16	P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. Stroke, 2021, 52, 2250-2257.	2.0	7
17	Restart TICrH: An Adaptive Randomized Trial of Time Intervals to Restart Direct Oral Anticoagulants after Traumatic Intracranial Hemorrhage. Journal of Neurotrauma, 2021, 38, 1791-1798.	3.4	10
18	Carotid Stenosis and Recurrent Ischemic Stroke. Stroke, 2021, 52, 2414-2417.	2.0	19

#	Article	lF	CITATIONS
19	Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke, 2021, 52, 3482-3489.	2.0	9
20	Intracranial Hemorrhage During Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2021, 78, 1372-1384.	2.8	17
21	Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke. JAMA Neurology, 2021, 78, 1091.	9.0	11
22	Cilostazol for Secondary Stroke Prevention. Stroke, 2021, 52, e635-e645.	2.0	17
23	Antiplatelet Use and Ischemic Stroke Risk in Minor Stroke or Transient Ischemic Attack: A Post Hoc Analysis of the POINT Trial. Stroke, 2021, 52, e773-e776.	2.0	5
24	Ticagrelor versus Clopidogrel in <i>CYP2C19</i> Loss-of-Function Carriers with Stroke or TIA. New England Journal of Medicine, 2021, 385, 2520-2530.	27.0	147
25	Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in <i>C</i> YP2C19 Loss-of-Function Allele Noncarriers With Overweight/Obesity. Stroke, 2020, 51, 224-231.	2.0	12
26	Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis. Neurology, 2020, 94, e181-e189.	1.1	4
27	Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. New England Journal of Medicine, 2020, 383, 207-217.	27.0	333
28	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke, 2020, 51, 3504-3513.	2.0	67
29	Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. Clinical Trials, 2020, 17, 617-626.	1.6	12
30	The Transformational Effects of COVID-19 on Medical Education. JAMA - Journal of the American Medical Association, 2020, 324, 1033.	7.4	164
31	Estimated Association of Construction Work With Risks of COVID-19 Infection and Hospitalization in Texas. JAMA Network Open, 2020, 3, e2026373.	5.9	48
32	Efficacy of Clopidogrel for Prevention of Stroke Based on <i>CYP2C19</i> Allele Status in the POINT Trial. Stroke, 2020, 51, 2058-2065.	2.0	26
33	Natalizumab in acute ischemic stroke (ACTION II). Neurology, 2020, 95, e1091-e1104.	1.1	55
34	Medical Education in Need of a 2020 Revamp. NEJM Catalyst, 2020, 1, .	0.7	0
35	Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial. Stroke, 2020, 51, 792-799.	2.0	35
36	Association of Black Race With Early Recurrence After Minor Ischemic Stroke or Transient Ischemic Attack. JAMA Neurology, 2020, 77, 601.	9.0	19

#	Article	IF	Citations
37	Cerebral small vessel disease or intracranial large vessel atherosclerosis may carry different risk for future strokes. Stroke and Vascular Neurology, 2020, 5, 128-137.	3.3	16
38	Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack. JAMA Neurology, 2019, 76, 1466.	9.0	148
39	Disability after minor stroke and TIA. Neurology, 2019, 93, e708-e716.	1.1	36
40	Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. Circulation, 2019, 140, 658-664.	1.6	63
41	Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials. Stroke, 2019, 50, 2187-2196.	2.0	13
42	Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial. JAMA Network Open, 2019, 2, e1910769.	5.9	12
43	The Risk and Cost of Limited Clinician and Patient Accountability in Health Care. JAMA - Journal of the American Medical Association, 2019, 322, 1759.	7.4	1
44	Academic Medical Centers. JAMA - Journal of the American Medical Association, 2019, 322, 203.	7.4	18
45	Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ: British Medical Journal, 2019, 365, 12211.	2.3	86
46	Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. International Journal of Stroke, 2019, 14, 908-914.	5.9	6
47	Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke. JAMA Neurology, 2019, 76, 774.	9.0	38
48	Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. BMJ: British Medical Journal, 2019, 364, l895.	2.3	21
49	Association Between <i>ABCB1</i> Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack. JAMA Neurology, 2019, 76, 552.	9.0	33
50	Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. Stroke, 2019, 50, 675-682.	2.0	3
51	The Acute S <u>t</u> roke or Transient Isc <u>h</u> emic Attack Treated with Tic <u>a</u> gre <u>l</u> or and Aspirin for Pr <u>e</u> vention of <u>S</u> trial: Rationale and design. International Journal of Stroke, 2019, 14, 745-751.	5.9	28
52	Comparative Effectiveness of Aspirin and Clopidogrel Versus Aspirin in Acute Minor Stroke or Transient Ischemic Attack. Stroke, 2019, 50, 101-109.	2.0	11
53	Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics Journal, 2018, 18, 713-720.	2.0	19
54	Neutrophil counts, neutrophil ratio, and new stroke in minor ischemic stroke or TIA. Neurology, 2018, 90, e1870-e1878.	1.1	47

#	Article	IF	Citations
55	Anticipating and Training the Physician of the Future: The Importance of Caring in an Age of Artificial Intelligence. Academic Medicine, 2018, 93, 1105-1106.	1.6	60
56	Development and validation of outcome prediction models for aneurysmal subarachnoid haemorrhage: the SAHIT multinational cohort study. BMJ: British Medical Journal, 2018, 360, j5745.	2.3	166
57	Dual Antiplatelet Therapy in Transient Ischemic Attack and Minor Stroke With Different Infarction Patterns. JAMA Neurology, 2018, 75, 711.	9.0	67
58	Leaving Tiny, Unruptured Intracranial Aneurysms Untreated. JAMA Neurology, 2018, 75, 13.	9.0	4
59	Elevated Neutrophil and Presence of Intracranial Artery Stenosis Increase the Risk of Recurrent Stroke, 2018, 49, 2294-2300.	2.0	27
60	The US Training System for Physicians—Need for Deeper Analysis. JAMA - Journal of the American Medical Association, 2018, 320, 982.	7.4	3
61	Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. New England Journal of Medicine, 2018, 379, 215-225.	27.0	844
62	Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA. Neurology, 2018, 91, e947-e955.	1.1	10
63	Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. Stroke, 2018, 49, 1678-1685.	2.0	20
64	Effect of Clopidogrel by Smoking Status on Secondary Stroke Prevention. Circulation, 2017, 135, 315-316.	1.6	17
65	Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 301-310.	10.2	174
66	Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA. Neurology, 2017, 88, 1081-1088.	1.1	32
67	Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack) Tj ETQq1	120078431	⊕rgBT /C∨
68	Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology, The, 2017, 16, 217-226.	10.2	176
69	Risks and benefits of clopidogrel–aspirin in minor stroke or TIA. Neurology, 2017, 88, 1906-1911.	1.1	47
70	Race-ethnicity on blood pressure control after ischemic stroke: a prospective cohort study. Journal of the American Society of Hypertension, 2017, 11, 38-44.	2.3	11
71	Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients. Stroke, 2017, 48, 167-173.	2.0	29
72	Recurrent Stroke in Minor Ischemic Stroke or Transient Ischemic Attack With Metabolic Syndrome and/or Diabetes Mellitus. Journal of the American Heart Association, 2017, 6, .	3.7	40

#	Article	IF	Citations
73	Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation. Stroke, 2017, 48, 1788-1794.	2.0	43
74	Voluntary Site Accreditation â€" Improving the Execution of Multicenter Clinical Trials. New England Journal of Medicine, 2017, 377, 1414-1415.	27.0	4
75	Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack. Stroke, 2017, 48, 3006-3011.	2.0	43
76	Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. Stroke, 2017, 48, 2480-2487.	2.0	19
77	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic) Tj ETQq1	1 0. 7843.	14 2g BT /Ove
78	Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack. Circulation, 2017, 135, 21-33.	1.6	200
79	Applying principles from the game theory to acute stroke care: Learning from the prisoner's dilemma, stag-hunt, and other strategies. International Journal of Stroke, 2016, 11, 274-286.	5. 9	7
80	Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016, 375, 35-43.	27.0	424
81	Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack. Stroke, 2016, 47, 2791-2796.	2.0	15
82	Endovascular Thrombectomy for Ischemic Stroke. JAMA - Journal of the American Medical Association, 2016, 316, 1265.	7.4	33
83	Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016, 375, 1394-1395.	27.0	7
84	Impact of Increased Early Statin Administration on Ischemic Stroke Outcomes: A Multicenter Electronic Medical Record Intervention. Journal of the American Heart Association, 2016, 5, .	3.7	8
85	Association Between <i>CYP2C19</i> Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA - Journal of the American Medical Association, 2016, 316, 70.	7.4	276
86	Treatment Effect of Clopidogrel Plus Aspirin Within 12ÂHours of Acute Minor Stroke or Transient Ischemic Attack. Journal of the American Heart Association, 2016, 5, e003038.	3.7	20
87	Improved Ischemic Stroke Outcome Prediction Using Model Estimation of Outcome Probability: The THRIVE-c Calculation. International Journal of Stroke, 2015, 10, 815-821.	5.9	19
88	Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (Socrates) Trial: Rationale and Design. International Journal of Stroke, 2015, 10, 1304-1308.	5.9	28
89	Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke. Neurology, 2015, 85, 573-579.	1.1	44
90	Prevalence, knowledge, and treatment of transient ischemic attacks in China. Neurology, 2015, 84, 2354-2361.	1.1	41

#	Article	IF	CITATIONS
91	Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial. Circulation, 2015, 132, 40-46.	1.6	178
92	Dual antiplatelet therapy in stroke and ICAS. Neurology, 2015, 85, 1154-1162.	1.1	158
93	Association of Lp-PLA ₂ -A and early recurrence of vascular events after TIA and minor stroke. Neurology, 2015, 85, 1585-1591.	1.1	43
94	Early Outcomes After Carotid Artery Stenting Compared With Endarterectomy for Asymptomatic Carotid Stenosis. Stroke, 2015, 46, 120-125.	2.0	41
95	Costâ€Effectiveness of Clopidogrelâ€Aspirin Versus Aspirin Alone for Acute Transient Ischemic Attack and Minor Stroke. Journal of the American Heart Association, 2014, 3, e000912.	3.7	28
96	Effect of Statin Use During Hospitalization for Intracerebral Hemorrhage on Mortality and Discharge Disposition. JAMA Neurology, 2014, 71, 1364.	9.0	72
97	Screen failure data in clinical trials: Are screening logs worth it?. Clinical Trials, 2014, 11, 467-472.	1.6	24
98	Letter by Elkins et al Regarding Article, "Blocking of α4 Integrin Does Not Protect From Acute Ischemic Stroke in Mice― Stroke, 2014, 45, e195.	2.0	1
99	A Simple Risk Index and Thrombolytic Treatment Response in Acute Ischemic Stroke. JAMA Neurology, 2014, 71, 848.	9.0	18
100	Recurrent Stroke was Associated with Poor Quality of Life in Patients with Transient Ischemic Attack or Minor Stroke: Finding from the <scp>CHANCE</scp> Trial. CNS Neuroscience and Therapeutics, 2014, 20, 1029-1035.	3.9	50
101	Decision Making in Acute Stroke Care. Stroke, 2014, 45, 2144-2150.	2.0	20
102	Deaths from stroke in US young adults, 1989–2009. Neurology, 2014, 83, 2110-2115.	1.1	39
103	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2014, 45, 2160-2236.	2.0	3,891
104	Clopidogrel with Aspirin in Minor Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2013, 369, 1375-1377.	27.0	15
105	Temporal and Geographic Trends in the Global Stroke Epidemic. Stroke, 2013, 44, S123-5.	2.0	58
106	Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2013, 369, 11-19.	27.0	1,384
107	Forecasting the Future of Stroke in the United States. Stroke, 2013, 44, 2361-2375.	2.0	636
108	Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design. International Journal of Stroke, 2013, 8, 479-483.	5.9	135

#	Article	IF	CITATIONS
109	Application of the ABCD ² Score to Identify Cerebrovascular Causes of Dizziness in the Emergency Department. Stroke, 2012, 43, 1484-1489.	2.0	99
110	Patent Foramen Ovale Closure â€" Closing the Door Except for Trials. New England Journal of Medicine, 2012, 366, 1048-1050.	27.0	30
111	Statin Use During Ischemic Stroke Hospitalization Is Strongly Associated With Improved Poststroke Survival. Stroke, 2012, 43, 147-154.	2.0	134
112	Ischemic Transient Neurological Events Identified by Immune Response to Cerebral Ischemia. Stroke, 2012, 43, 1006-1012.	2.0	38
113	Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack. Stroke, 2012, 43, 881-883.	2.0	92
114	A Cross-Sectional Study of Individuals Seeking Information on Transient Ischemic Attack and Stroke Symptoms Online: A Target for Intervention?. PLoS ONE, 2012, 7, e47997.	2.5	4
115	Urgent neurology consultation from the ED for transient ischemic attack. American Journal of Emergency Medicine, 2011, 29, 601-608.	1.6	8
116	Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. Stroke, 2011, 42, 227-276.	2.0	1,433
117	Metrics for Measuring Quality of Care in Comprehensive Stroke Centers: Detailed Follow-Up to Brain Attack Coalition Comprehensive Stroke Center Recommendations. Stroke, 2011, 42, 849-877.	2.0	158
118	Effect of Clopidogrel plus ASA vs. ASA Early after TIA and Ischaemic Stroke: A Substudy of the CHARISMA Trial. International Journal of Stroke, 2011, 6, 3-9.	5.9	73
119	The China National Stroke Registry for Patients with Acute Cerebrovascular Events: Design, Rationale, and Baseline Patient Characteristics. International Journal of Stroke, 2011, 6, 355-361.	5.9	227
120	Enhancing ties between academia and industry to improve health. Nature Medicine, 2011, 17, 434-436.	30.7	19
121	Prevention of Stroke Following Transient Ischemic Attack. Current Atherosclerosis Reports, 2011, 13, 330-337.	4.8	7
122	National stroke association recommendations for systems of care for transient ischemic attack. Annals of Neurology, 2011, 69, 872-877.	5. 3	42
123	Risk of Vascular Events in Emergency Department Patients Discharged Home With Diagnosis of Dizziness or Vertigo. Annals of Emergency Medicine, 2011, 57, 34-41.	0.6	82
124	A Cost–Utility Analysis of Mechanical Thrombectomy as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Large-Vessel Ischemic Stroke. Stroke, 2011, 42, 2013-2018.	2.0	48
125	Forecasting the Future of Cardiovascular Disease in the United States. Circulation, 2011, 123, 933-944.	1.6	2,690
126	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart, 2011, 97, 626-631.	2.9	13

#	Article	IF	CITATIONS
127	Intracranial Large Vessel Occlusion as a Predictor of Decline in Functional Status After Transient Ischemic Attack. Stroke, 2011, 42, 44-47.	2.0	36
128	Validation of the Stroke Prognostic Instrument-II in a Large, Modern, Community-Based Cohort of Ischemic Stroke Survivors. Stroke, 2011, 42, 3392-3396.	2.0	25
129	Global Variation in the Relative Burden of Stroke and Ischemic Heart Disease. Circulation, 2011, 124, 314-323.	1.6	320
130	Stroke prediction after TIA: avoiding an alphabet soup. Lancet Neurology, The, 2010, 9, 1039-1040.	10.2	3
131	Standardized discharge orders after stroke: Results of the quality improvement in stroke prevention (QUISP) cluster randomized trial. Annals of Neurology, 2010, 67, 579-589.	5. 3	29
132	Gender Differences in Treatment of Severe Carotid Stenosis After Transient Ischemic Attack. Stroke, 2010, 41, 1891-1895.	2.0	38
133	Effect of Clopidogrel on the Rate and Functional Severity of Stroke Among High Vascular Risk Patients. Stroke, 2010, 41, 1679-1683.	2.0	22
134	The Economic Case for New Stroke Thrombolytics. Stroke, 2010, 41, S59-62.	2.0	14
135	Addition of Brain Infarction to the ABCD ² Score (ABCD ² I). Stroke, 2010, 41, 1907-1913.	2.0	158
136	Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. American Heart Journal, 2010, 160, 380-386.e1.	2.7	90
137	<i>C</i> linical- and <i>I</i> maging-Based <i>P</i> rediction of Stroke Risk After Transient Ischemic Attack. Stroke, 2009, 40, 181-186.	2.0	117
138	Definition and Evaluation of Transient Ischemic Attack. Stroke, 2009, 40, 2276-2293.	2.0	1,543
139	Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurology, The, 2009, 8, 345-354.	10.2	823
140	Stroke mortality in the Seychelles: methodological issues – Authors' reply. Lancet Neurology, The, 2009, 8, 700.	10.2	0
141	Intracranial atherosclerotic disease: An update. Annals of Neurology, 2009, 66, 730-738.	5.3	101
142	Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Archives of Cardiovascular Diseases, 2009, 102, 485-496.	1.6	30
143	Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke, 2008, 39, 1647-1652.	2.0	450
144	Predictors of Rehemorrhage After Treatment of Ruptured Intracranial Aneurysms. Stroke, 2008, 39, 120-125.	2.0	433

#	Article	IF	Citations
145	Chapter 23 Identification, risks, and treatment of transient ischemic attack. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 93, 453-473.	1.8	O
146	Factors Associated With the Decision to Hospitalize Patients After Transient Ischemic Attack Before Publication of Prediction Rules. Stroke, 2008, 39, 411-413.	2.0	13
147	Higher ABCD ² Score Predicts Patients Most Likely to Have True Transient Ischemic Attack. Stroke, 2008, 39, 3096-3098.	2.0	103
148	Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. Circulation, 2008, 118, 1705-1712.	1.6	210
149	Trends in Usage of Alternative Antiplatelet Therapy After Stroke and Transient Ischemic Attack. Stroke, 2008, 39, 1228-1232.	2.0	13
150	Response to Letter by O'Kelly and Macdonald. Stroke, 2008, 39, .	2.0	0
151	The 2008 William M. Feinberg Lecture. Stroke, 2008, 39, 3431-3436.	2.0	6
152	Evaluation and management of transient ischemic attack: an important component of stroke prevention. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 310-318.	3.3	16
153	Transient Neurological Attack. JAMA - Journal of the American Medical Association, 2007, 298, 2912.	7.4	7
154	Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet, The, 2007, 369, 283-292.	13.7	1,160
155	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	2.8	752
156	Early editorial manuscript screening versus obligate peer review: A randomized trial. Annals of Neurology, 2007, 61, A10-A12.	5.3	13
157	Towards FASTER treatment of TIA and minor stroke. Lancet Neurology, The, 2007, 6, 941-943.	10.2	3
158	Short-term prognosis after a TIA: a simple score predicts risk Cleveland Clinic Journal of Medicine, 2007, 74, 729-736.	1.3	17
159	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke, 2006, 37, 577-617.	2.0	1,510
160	Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet, The, 2006, 367, 1319-1327.	13.7	135
161	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. Circulation, 2006, 113, .	1.6	416
162	Recent advances in management of transient ischaemic attacks and minor ischaemic strokes. Lancet Neurology, The, 2006, 5, 323-331.	10.2	153

#	Article	IF	Citations
163	National Stroke Association guidelines for the management of transient ischemic attacks. Annals of Neurology, 2006, 60, 301-313.	5.3	178
164	Transient Ischemic Attacks. Stroke, 2006, 37, 320-322.	2.0	27
165	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	27.0	2,582
166	Transient ischemic attack: A neurologic emergency. Current Neurology and Neuroscience Reports, 2005, 5, 13-20.	4.2	17
167	Editorial Comment— Transient Ischemic Attacks Are Emergencies. Stroke, 2005, 36, 724-724.	2.0	19
168	Is hospitalization after TIA cost-effective on the basis of treatment with tPA?. Neurology, 2005, 65, 1799-1801.	1.1	84
169	Transient Ischemic Attack: A Dangerous Harbinger and an Opportunity to Intervene. Seminars in Neurology, 2005, 25, 362-370.	1.4	11
170	Chlamydia pneumoniae Burden in Carotid Arteries Is Associated With Upregulation of Plaque Interleukin-6 and Elevated C-Reactive Protein in Serum. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2648-2653.	2.4	34
171	Antihypertensive Medications Prescribed at Discharge After an Acute Ischemic Cerebrovascular Event. Stroke, 2005, 36, 1944-1947.	2.0	28
172	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2005, 150, 401.e1-401.e7.	2.7	29
173	Longitudinal Risk of Intracranial Hemorrhage in Patients With Arteriovenous Malformation of the Brain Within a Defined Population. Stroke, 2004, 35, 1697-1702.	2.0	240
174	Poststroke Neurological Improvement Within 7 Days Is Associated With Subsequent Deterioration. Stroke, 2004, 35, 2165-2170.	2.0	21
175	Ischemic Preconditioning From Transient Ischemic Attacks?. Stroke, 2004, 35, 2680-2682.	2.0	86
176	Hospital Usage of Early Do-Not-Resuscitate Orders and Outcome After Intracerebral Hemorrhage. Stroke, 2004, 35, 1130-1134.	2.0	302
177	External Validation of the ICH Score. Neurocritical Care, 2004, 1, 53-60.	2.4	123
178	Cognitive Impairment and Decline Are Associated with Carotid Artery Disease in Patients without Clinically Evident Cerebrovascular Disease. Annals of Internal Medicine, 2004, 140, 237.	3.9	253
179	Early recovery after cerebral ischemia risk of subsequent neurological deterioration. Annals of Neurology, 2003, 54, 439-444.	5. 3	62
180	Diffusion-weighted MRI in evaluation of transient ischemic attack. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 137-142.	1.6	13

#	Article	IF	CITATIONS
181	Knowledge and management of transient ischemic attacks among US primary care physicians. Neurology, 2003, 61, 1455-1456.	1.1	24
182	A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA. Neurology, 2003, 60, 280-285.	1.1	97
183	Are Patients With Acutely Recovered Cerebral Ischemia More Unstable?. Stroke, 2003, 34, 2446-2450.	2.0	63
184	Head Computed Tomography Findings Predict Short-Term Stroke Risk After Transient Ischemic Attack. Stroke, 2003, 34, 2894-2898.	2.0	129
185	Thirty-Year Projections for Deaths From Ischemic Stroke in the United States. Stroke, 2003, 34, 2109-2112.	2.0	76
186	Safety and feasibility of a CT protocol for acute stroke: combined CT, CT angiography, and CT perfusion imaging in 53 consecutive patients. American Journal of Neuroradiology, 2003, 24, 688-90.	2.4	95
187	Electrocardiographic Findings Predict Short-term Cardiac Morbidity After Transient Ischemic Attack. Archives of Neurology, 2002, 59, 1437-41.	4.5	34
188	Modeling Treatment Effects on Binary Outcomes with Grouped-Treatment Variables and Individual Covariates. American Journal of Epidemiology, 2002, 156, 753-760.	3.4	52
189	Effects of the September 11th attacks on urgent and emergent medical evaluations in a Northern California managed care plan. American Journal of Medicine, 2002, 113, 556-562.	1.5	12
190	Transient Ischemic Attack. New England Journal of Medicine, 2002, 347, 1687-1692.	27.0	163
190	Transient Ischemic Attack. New England Journal of Medicine, 2002, 347, 1687-1692. The ICH Score. Stroke, 2001, 32, 891-897.	27.0	1,851
191	The ICH Score. Stroke, 2001, 32, 891-897.	2.0	1,851
191 192	The ICH Score. Stroke, 2001, 32, 891-897. Characteristics of Academic Medical Centers and Ischemic Stroke Outcomes. Stroke, 2001, 32, 2137-2142.	2.0	1,851 64
191 192 193	The ICH Score. Stroke, 2001, 32, 891-897. Characteristics of Academic Medical Centers and Ischemic Stroke Outcomes. Stroke, 2001, 32, 2137-2142. Treatment of Unruptured Cerebral Aneurysms in California. Stroke, 2001, 32, 597-605. Effect of Endovascular Services and Hospital Volume on Cerebral Aneurysm Treatment Outcomes.	2.0	1,851 64 227
191 192 193	The ICH Score. Stroke, 2001, 32, 891-897. Characteristics of Academic Medical Centers and Ischemic Stroke Outcomes. Stroke, 2001, 32, 2137-2142. Treatment of Unruptured Cerebral Aneurysms in California. Stroke, 2001, 32, 597-605. Effect of Endovascular Services and Hospital Volume on Cerebral Aneurysm Treatment Outcomes. Stroke, 2000, 31, 111-117.	2.0	1,851 64 227 171
191 192 193 194	The ICH Score. Stroke, 2001, 32, 891-897. Characteristics of Academic Medical Centers and Ischemic Stroke Outcomes. Stroke, 2001, 32, 2137-2142. Treatment of Unruptured Cerebral Aneurysms in California. Stroke, 2001, 32, 597-605. Effect of Endovascular Services and Hospital Volume on Cerebral Aneurysm Treatment Outcomes. Stroke, 2000, 31, 111-117. Prognostication matters., 2000, 23, 839-842. Endovascular and surgical treatment of unruptured cerebral aneurysms: Comparison of risks. Annals	2.0 2.0 2.0	1,851 64 227 171

#	Article	IF	CITATIONS
199	Practice Variability in Management of Transient Ischemic Attacks. European Neurology, 1999, 42, 105-108.	1.4	65
200	Central apnea and acute cardiac ischemia in a sheep model of epileptic sudden death. Annals of Neurology, 1997, 42, 588-594.	5. 3	110
201	Postictal Pulmonary Edema Requires Pulmonary Vascular Pressure Increases. Epilepsia, 1996, 37, 428-432.	5.1	46
202	The role of hypoventilation in a sheep model of epileptic sudden death. Annals of Neurology, 1995, 37, 531-537.	5. 3	133
203	Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack. Stroke, 0, , .	2.0	1
204	No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. Neurological Research, 0, , 1-7.	1.3	0